Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Kemeny, Stav ^a,b   Dery, Dikla ^a   Loboda, Yelena ^b   Rovner, Marshall ^a   Lev, Tali ^a   Zuri, Dotan ^a   Finberg, John P M ^b   Larisch, Sarit ^a  

^a UNIVERSITY OF HAIFA   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; MITOCHONDRIAL PROTEIN; PARKIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; MALE; MITOCHONDRION; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; APOPTOSIS; BRAIN; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; MALE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; SEPTINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

RATTUS;

EID: 84863611344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038837     Document Type: Article

References (93)

1. Dawson VL, Dawson TM, (1995) Physiological and toxicological actions of nitric oxide in the central nervous system. Adv Pharmacol 34: 323-342.
2. Morley JF, Hurtig HI, (2010) Current understanding and management of Parkinson disease: five new things. Neurology 75: S9-15.
3. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608.
4. Matsumine H, Hattori N, Mizuno Y, (2001) Autosomal Recessive Juvenile Parkinsonism (AR-JP): Genetic Diagnosis. In: Mouradian MM, editors. pp. 13-29 editor. Parkinson's Disease Methods and Protocols. Totowa, NJ: Humana Press Inc.
5. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, et al. (2003) Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60: 796-801.
6. Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, et al. (2003) Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Annals of Neurology 53: 624-629.
7. Lu B, (2004) Putting a PARKINg brake on neurodegeneration. Mol Psychiatry 9: 6-7.
8. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305.
9. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, et al. (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 97: 13354-13359.
10. Dawson TM, Dawson VL, (2010) The role of parkin in familial and sporadic Parkinson's disease. Movement Disorders 25: S32-S39.
11. Glickman MH, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428.
12. Goldberg AL, (2007) Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35: 12-17.
13. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, et al. (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 22: 1901-1911.
14. Olanow CW, (2007) The pathogenesis of cell death in Parkinson's disease- 2007. Mov Disord 22: S335-S342.
15. Goetz CG, Damier P, Hicking C, Laska E, Muller T, et al. (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 22: 179-186.
16. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, et al. (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A 105: 1638-1643.
17. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, et al. (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12: 517-526.
18. Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z, et al. (2006) Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther 14: 716-723.
19. Dawson TM, Dawson VL, (2003) Molecular Pathways of Neurodegeneration in Parkinson's Disease. Science 302: 819-822.
20. Dawson TM, Dawson VL, (2002) Neuroprotective and neurorestorative strategies for Parkinson's disease. Nature Neuroscience.
21. Rosen KM, Moussa CE, Lee HK, Kumar P, Kitada T, et al. (2009) Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function. J Neurosci Res 88: 167-178.
22. Ribe EM, Serrano-Saiz E, Akpan N, Troy CM, (2008) Mechanisms of neuronal death in disease: defining the models and the players. Biochem J 415: 165-182.
23. Prunell GF, Troy CM, (2004) Balancing neuronal death. J Neurosci Res 78: 1-6.
24. Bredesen DE, Rao RV, Mehlen P, (2006) Cell death in the nervous system. Nature 443: 796-802.
25. Bergmann A, Steller H, (2010) Apoptosis, stem cells, and tissue regeneration. Sci Signal 3: re8.
26. Friedlander RM, Yuan J, (1998) ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ 5: 823-831.
27. Abraham MC, Shaham S, (2007) Necrosis and the serpin under't. Dev Cell 13: 464-465.
28. Fulda S, (2009) Tumor resistance to apoptosis. Int J Cancer 124: 511-515.
29. Deveraux QL, Takahashi R, Salvesen GS, Reed JC, (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300-304.
30. Lee TV, Fan Y, Wang S, Srivastava M, Broemer M, et al. (2011) Drosophila IAP1-mediated ubiquitylation controls activation of the initiator caspase DRONC independent of protein degradation. PLoS Genet 7: e1002261.
31. Salvesen GS, Duckett CS, (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410.
32. Sun C, Cai M, Meadows RP, Xu N, Gunasekera AH, et al. (2000) NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 275: 33777-33781.
33. Gottfried Y, Rotem A, Lotan R, Steller H, Larisch S, (2004) The mitochondrial ARTS protein promotes apoptosis through targeting XIAP. EMBO J 23: 1627-1635.
34. Larisch-Bloch S, Danielpour D, Roche NS, Lotan R, Hsing AY, et al. (2000) Selective loss of the transforming growth factor-beta apoptotic signaling pathway in mutant NRP-154 rat prostatic epithelial cells. Cell Growth Differ 11: 1-10.
35. Larisch S, Yi Y, Lotan R, Kerner H, Eimerl S, et al. (2000) A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol 2: 915-921.
36. Lotan R, Rotem A, Gonen H, Finberg JP, Kemeny S, et al. (2005) Regulation of the proapoptotic ARTS protein by ubiquitin-mediated degradation. J Biol Chem 280: 25802-25810.
37. Edison N, Reingewertz TH, Gottfried Y, Lev T, Zuri D, et al. (2012) Peptides mimicking the unique ARTS-XIAP binding site promote apoptotic cell death in cultured cancer cells. Clin Cancer Res.
38. Garcia-Fernandez M, Kissel H, Brown S, Gorenc T, Schile AJ, et al. (2010) Sept4/ARTS is required for stem cell apoptosis and tumor suppression. Genes Dev 24: 2282-2293.
39. McCarthy N, (2010) The ARTS of cell death. Nat Rev Cancer 10: 816.
40. Edison N, Zuri D, Maniv I, Bornstein B, Lev T, et al. (2011) The IAP-antagonist ARTS initiates caspase activation upstream of cytochrome C and SMAC/Diablo. Cell Death Differ.
41. Bornstein B, Gottfried Y, Edison N, Shekhtman A, Lev T, et al. (2011) ARTS binds to a distinct domain in XIAP-BIR3 and promotes apoptosis by a mechanism that is different from other IAP-antagonists. Apoptosis. 2011/06/23 ed.
42. Bornstein B, Edison N, Gottfried Y, Lev T, Shekhtman A, et al. (2012) X-linked Inhibitor of Apoptosis Protein promotes the degradation of its antagonist, the pro-apoptotic ARTS protein. Int J Biochem Cell Biol 44: 489-495.
43. Carp MJ, Larisch S, (2008) Septins and Apoptosis. In: Hall PA, Russell SEH, Pringle JR, editors. pp. 281-295 editors. The Septins. London: Wiley Blackwell.
44. Hall PA, Russell SE, (2004) The pathobiology of the septin gene family. J Pathol 204: 489-505.
45. Longtine MS, DeMarini DJ, Valencik ML, Al-Awar OS, Fares H, et al. (1996) The septins: roles in cytokinesis and other processes. Curr Opin Cell Biol 8: 106-119.
46. Choi P, Snyder H, Petrucelli L, Theisler C, Chong M, et al. (2003) SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res 117: 179-189.
47. Zieger B, Tran H, Hainmann I, Wunderle D, Zgaga-Griesz A, et al. (2000) Characterization and expression analysis of two human septin genes, PNUTL1 and PNUTL2. Gene 261: 197-203.
48. Ihara M, Tomimoto H, Kitayama H, Morioka Y, Akiguchi I, et al. (2003) Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem 278: 24095-24102.
49. Elhasid R, Sahar D, Merling A, Zivony Y, Rotem A, et al. (2004) Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients. Oncogene 23: 5468-5475.
50. Finberg JPM, Gluzman Z, Reshef M, Loboda Y, Mohsen U, et al. (2010) Modulation of excessive neuronal activity by fibroblasts: potential use in treatment of Parkinson's disease. Restorative Neurology and Neuroscience 28: 803-815.
51. Gottfried Y, Rotem A, Klein E, Larisch S, (2007) The pro-apoptotic ARTS/Sept4 protein is significantly reduced in post-mortem brains from schizophrenic patients. Schizophr Res 96: 257-266.
52. Perez-Polo JR, Tiffany-Castiglioni E, Ziegler MG, Werrbach-Perez K, (1982) Effect of nerve growth factor on catecholamine metabolism in a human neuroblastoma clone (SY5Y). Dev Neurosci 5: 418-423.
53. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, et al. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7: 1144-1150.
54. Shehadeh L, Mitsi G, Adi N, Bishopric N, Papapetropoulos S, (2009) Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. Mov Disord 24: 204-210.
55. Simola N, Morelli M, Carta A, (2007) The 6-Hydroxydopamine model of parkinson's disease. Neurotoxicity Research 11: 151-167.
56. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, et al. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172.
57. Liang ZQ, Li YL, Zhao XL, Han R, Wang XX, et al. (2007) NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res 1145: 190-203.
58. Turmel H, Hartmann A, Parain K, Douhou A, Srinivasan A, et al. (2001) Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Mov Disord 16: 185-189.
59. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, et al. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269.
60. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B, (2003) Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37: 911-924.
61. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, et al. (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 25: 2002-2009.
62. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, et al. (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 8: 834-842.
63. Corti O, Hampe C, Koutnikova H, Darios F, Jacquier S, et al. (2003) The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 12: 1427-1437.
64. Ron I, Rapaport D, Horowitz M, (2010) Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum Mol Genet 19: 3771-3781.
65. Joch M, Ase AR, Chen CX, MacDonald PA, Kontogiannea M, et al. (2007) Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol Biol Cell 18: 3105-3118.
66. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, et al. (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-92.
67. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
68. Kubbutat MH, Jones SN, Vousden KH, (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303.
69. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, et al. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
70. Laine A, Ronai Z, (2007) Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 26: 1477-1483.
71. Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, et al. (2008) Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 283: 3316-3328.
72. Garrison JB, Correa RG, Gerlic M, Yip KW, Krieg A, et al. (2011) ARTS and Siah collaborate in a pathway for XIAP degradation. Mol Cell 41: 107-116.
73. Liani E, Eyal A, Avraham E, Shemer R, Szargel R, et al. (2004) Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A 101: 5500-5505.
74. Tatton WG, Olanow CW, (1999) Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochimica et Biophysica Acta (BBA)- Bioenergetics 1410: 195-213.
75. Singh S, Dikshit M, (2007) Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res Rev 54: 233-250.
76. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, et al. (1999) Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 45: 668-672.
77. Mouatt-Prigent A, Muriel MP, Gu WJ, El Hachimi KH, Lucking CB, et al. (2004) Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia. J Neural Transm 111: 1209-1218.
78. Kuroda Y, Mitsui T, Kunishige M, Matsumoto T, (2006) Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem Biophys Res Commun 348: 787-793.
79. Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, et al. (2006) Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15: 883-895.
80. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, et al. (2011) Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum Mol Genet.
81. Xie H, Surka M, Howard J, Trimble WS, (1999) Characterization of the mammalian septin H5: distinct patterns of cytoskeletal and membrane association from other septin proteins. Cell Motil Cytoskeleton 43: 52-62.
82. Narendra D, Tanaka A, Suen DF, Youle RJ, (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183: 795-803.
83. Wild P, Dikic I, (2010) Mitochondria get a Parkin' ticket. Nat Cell Biol 12: 104-106.
84. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, et al. (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8: e1000298.
85. Ulusoy A, Kirik D, (2008) Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease? Exp Neurol 212: 258-260.
86. da Costa CA, Sunyach C, Giaime E, West A, Corti O, et al. (2009) Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 11: 1370-1375.
87. Yi CH, Yuan J, (2009) The Jekyll and Hyde functions of caspases. Dev Cell 16: 21-34.
88. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M, (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981-989.
89. Kuo CT, Zhu S, Younger S, Jan LY, Jan YN, (2006) Identification of E2/E3 ubiquitinating enzymes and caspase activity regulating Drosophila sensory neuron dendrite pruning. Neuron 51: 283-290.
90. Williams DW, Kondo S, Krzyzanowska A, Hiromi Y, Truman JW, (2006) Local caspase activity directs engulfment of dendrites during pruning. Nat Neurosci 9: 1234-1236.
91. Morrish PK, Sawle GV, Brooks DJ, (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119 (Pt 2): 585-591.
92. Braak H, Braak E, (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand pp. 3-12.
93. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, et al. (1996) New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J Neural Transm pp. 1-6.